A division of global drug giant
Glaxo, GlaxoSmithKline Biologicals based in Belgium is in talks with the
Hyderabad-based Biological E Ltd (BE) to purchase its vaccines division.
This vaccine division produces and markets a range of pediatric and adult vaccines. The Diphtheria and Tetanus vaccine has given the company a sizeable market share in the Indian vaccine market. BE claims to be the first private sector company to enter the vaccines market.
Recently Glaxo's current plant in Nasik faced some constraints in supplying vaccines and therefore it would be interested in buying companies with modern manufacturing facilities approved by international agencies like US FDA. The BE vaccine unit buyout will give GSK Biologicals additional capacity in India.